Policy
LAST REVIEWED 2026-06-30 · 815 SOURCES · 0 CORRECTIONS
Educational policy tracking only. This is not legal advice, medical advice, treatment access guidance, or a substitute for checking current law with qualified counsel.
Policy rows distinguish federal status, state bills, research funding, trial authorization, and treatment access. State coverage includes all 50 states and DC, with high-priority rows shown first. A bill, fiscal note, or agency announcement is not clinical proof and does not override federal law unless the source says so.
Establishes the federal baseline that Ibogaine is listed in Schedule I under U.S. controlled-substances regulations. Does not authorize medical treatment, prescribing, clinic access, or state-level exceptions that override federal law.
DemeRx NB may begin a phase I noribogaine hydrochloride study in a closely monitored U.S. clinical setting. Not FDA approval, not proof of safety or effectiveness, and not a general treatment access pathway.
The proposal would have appropriated state funds for a certified clinical research study on Ibogaine for neurological diseases. This tracker does not treat the proposal as current access or an enacted 2026 program without a newer official status source.
Creates an Ibogaine research pilot program lane, allows up to five pilot sites, includes possible rulemaking around administration/manufacturing/use, and adds benefit-sharing language tied to Indigenous communities. Does not make unsupervised Ibogaine use lawful and should not be read as FDA approval, proof of efficacy, or a provider referral pathway.
Establishes a state framework for Ibogaine research and intellectual-property development through a public-private partnership approach. The enacted framework does not create general treatment access or FDA approval.
The bill record describes psychedelic-assisted therapy legislation and has included Ibogaine-related clinical-study discussion in public tracking. Do not treat this as final law or treatment access until final enrollment/signature status is confirmed.
Would establish an Ibogaine Clinical Research Grant Program and include it as an authorized use of Opioid Restitution Fund money. Introduced/hearing activity is not enactment and does not authorize treatment access.
Creates a state framework for an Ibogaine drug-development clinical trial consortium and coordination with a lead consortium in another state. Does not provide routine clinical access; treatment-administration provisions depend on FDA approval or lawful federal authorization.
Creates and maintains a temporary study committee to evaluate Ibogaine treatment issues and make legislative recommendations. A study committee is not legalization, treatment access, a clinical trial authorization, or FDA approval.
Creates a state framework related to Ibogaine clinical trials and drug-development requirements. Does not make Ibogaine FDA-approved and does not by itself authorize unsupervised treatment or provider referral.
Would authorize scientific research and clinical trials related to Ibogaine with registration and immunity language. Introduced/referred language is not enactment and does not create general treatment access.
Would allow an attending physician to provide Ibogaine to a patient for specified disorders and exempt specified use from controlled-substance definition if enacted. As an in-committee bill, it does not create current legal access or override federal law.
In 2023, W. Bryan Hubbard, then chairing the Kentucky Opioid Abatement Advisory Commission, proposed dedicating roughly $42 million in opioid-settlement funds to ibogaine research. Hubbard was asked to resign in December 2023, and the reconstituted commission rejected the Kentucky ibogaine proposal on January 4, 2024. The Kentucky episode is documented here as carefully as the states that moved forward: a high-profile proposal that did not become policy.
Texas Senate Bill 2308 (89th Legislature, 2025), authored by State Senator Tan Parker, established a state-backed ibogaine clinical-research effort. In December 2025 the University of Texas Medical Branch (UTMB), with UTHealth Houston, was awarded $50 million by the state to lead ibogaine clinical trials for opioid use disorder and other conditions. A state appropriation and an FDA-authorized trial program are not FDA approval, not treatment access, and not proof that ibogaine works or is safe.
Source-labeled records for the people driving recent ibogaine policy activity. A policy proposal is not clinical proof and does not create legal treatment access.
Policy advocacy
Hubbard is the policy figure behind Kentucky's opioid-settlement ibogaine proposal and later Texas-facing advocacy.
What this does not prove: A policy proposal, whether adopted or withdrawn, is not clinical proof and does not create legal treatment access.
NPR: Kentucky backs away from ibogaine settlement plan · Kentucky Lantern: Texas funds trials after Kentucky demurred
Search records →